KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Rigel Pharmaceuticals (RIGL) over the last 17 years, with Q3 2025 value amounting to $137.1 million.

  • Rigel Pharmaceuticals' Cash & Current Investments rose 12440.52% to $137.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.1 million, marking a year-over-year increase of 12440.52%. This contributed to the annual value of $77.3 million for FY2024, which is 3581.05% up from last year.
  • As of Q3 2025, Rigel Pharmaceuticals' Cash & Current Investments stood at $137.1 million, which was up 12440.52% from $108.4 million recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' Cash & Current Investments registered a high of $153.4 million during Q2 2021, and its lowest value of $39.3 million during Q1 2021.
  • Moreover, its 5-year median value for Cash & Current Investments was $77.1 million (2025), whereas its average is $84.2 million.
  • Per our database at Business Quant, Rigel Pharmaceuticals' Cash & Current Investments tumbled by 5898.4% in 2021 and then skyrocketed by 17327.23% in 2022.
  • Rigel Pharmaceuticals' Cash & Current Investments (Quarter) stood at $125.0 million in 2021, then crashed by 53.42% to $58.2 million in 2022, then decreased by 2.19% to $56.9 million in 2023, then surged by 35.81% to $77.3 million in 2024, then skyrocketed by 77.37% to $137.1 million in 2025.
  • Its last three reported values are $137.1 million in Q3 2025, $108.4 million for Q2 2025, and $77.1 million during Q1 2025.